AntagomiR-199a enhances the liver protective effect of hypoxia-preconditioned BM-MSCs in a rat model of reduced-size liver transplantation.
Reduced-size liver transplantation was invented to overcome the shortage of donor livers; however, it has proven to be more susceptible to ischemia-reperfusion injury. Bone marrow derived mesenchymal stem cells (BM-MSCs) infusion has been shown to be protective following liver transplantation. Optimization of MSC infusion has been performed, among which hypoxia preconditioning and miRNA modulation have shown promise. MiR-199a inhibition was reported to induce angioneogenesis; however, whether mir-199a inhibition enhances the protective effect of BM-MSCs in liver transplantation remains unknown. In this study, we combined antagomiR-199a with hypoxia-preconditioned MSC infusion to discuss their effect and mechanism in a rat model of reduced-size liver transplantation. A reduced-size liver transplantation model was constructed and hypoxia-preconditioned MSCs (H-MSC) were intra-portally injected during operation. AgomiR-199a and antagomir-199a were injected through the caudal vein once a day after liver transplantation. The level of apoptosis and pro-inflammatory cytokines were measured An anti-VEGF antibody was injected to further explore the underlying mechanism. AntagomiR-199a plus H-MSC not only significantly decreased ALT and AST 72 h after LT, but also ameliorated the level of apoptosis and inhibited inflammatory reactions. On the contrary, agomir-199a reduced the protective effect of the H-MSC infusion. In terms of mechanism, the liver protective effect of miR-199a inhibition was abolished by treatment with a VEGF neutralizing antibody. AntagomiR-199a enhanced the protective effect of H-MSCs infusion via activation of the Hif-1α/VEGF axis.